Therapeutic resistance continues to be an indominable foe in our ambition for curative
cancer treatment. Recent insights into the molecular determinants of acquired treatment …

Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options,
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …

The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the
diagnosis and treatment of adults with AML based on clinical trials that have led to …

This study investigated the efficacy and safety of azacitidine maintenance in the
posttransplant setting based on the encouraging phase 1/2 reports for azacitidine …

Acute myeloid leukaemia (AML) incidence is age dependent, rising markedly in patients
aged! 60 years. Ageing of the European population may therefore contribute to the reported …

This phase 2 study was designed to compare systemic decitabine exposure, demethylation
activity, and safety in the first 2 cycles with cedazuridine 100 mg/decitabine 35 mg vs …

Background: Older adults with acute myeloid leukemia (AML) represent a vulnerable
population in whom disease-based and clinical risk factors, patient goals, prognosis, and …

Up to 18% of patients with acute myeloid leukemia (AML) present with a white blood cell
(WBC) count of greater than 100,000/µL, a condition that is frequently referred to as …

Abstract The coronavirus disease 2019 (COVID-19) pandemic poses several challenges to
the management of patients with leukemia. The biology of each leukemia and its …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …